Fox Business - The Power to Prosper
Search Site

Wednesday, April 7, 2010 as of 11:14 AM ET

Merck

More Headlines »« Less Headlines

Merck may refer to:

Read More at Wikipedia ›

Related Topics

  1. Vertex Pharmaceuticals
  2. 3M
  3. Fosamax
  4. Eli Lilly
  5. Mylan
  6. IMS Health
Get updates on Merck
J&J's Simponi Helps Colitis Patients In Clinical Trial

Johnson & Johnson (JNJ) said its drug Simponi improved symptoms in a majority of patients with an inflammatory-bowel disease in a new clinical trial.

The results, released at a medical conference Monday, could support expansion of the approved uses of Simponi to include treating the bowel condition, known as ulcerative colitis, which J&J estimates affects about 700,000 people in the U.S.Simponi, which was introduced in 2009, is currently approved to treat signs and symptoms of moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis.Simponi is known as an anti-tumor necrosis factor, or anti-TNF, a category that also includes J&J's older drug, Remicade, which is already approved to treat ulcerative colitis. Simponi can be self-administered by patients as an injection, while Remicade requires intravenous infusion by a health-care provider.J&J recorded $410 million in Simponi sales for 2011; Merck & Co. (MRK), which markets the drug in certain c...

Read More ›

  1. Stocks Rise as Solid Earnings Trump GDP Data

    FOX Business: The Power to ProsperWall Street ticked higher on Friday as strong corporate results helped traders overcome a weaker-than-expected reading on U.S. econ...

  2. Stocks Jump on Week Amid Solid Corporate Earnings

    FOX Business: The Power to ProsperWall Street posted a solid performance this week, with the major market averages all rallying more than 1% after several big-name c...

  3. Merck 1Q Net Rises 67% On Lower Costs; Sales Growth Slows

    Merck & Co. (MRK) reported a 67% increase in first-quarter profit on lower costs, while a deceleration in sales growth for blockbuster diabetes drug Januvia and a de...

  4. Merck Stirs Up 67% Jump in 1Q Profit

    Merck (NYSE:MRK) reported a 67% jump in first-quarter profit on Friday as tighter cost controls and strong diabetes drug sales helped offset softer sales from arthri...

  5. Stock Futures Climb as Traders Shrug Off GDP Miss

    FOX Business: The Power to ProsperU.S. stock index futures climbed modestly on Friday as traders remained confident about American corporations' profitability despit...

  6. Merck Profit Rises

    Merck & Co. Inc said on Friday that its first-quarter profit rose to $1.74 billion, or 56 cents a share, compared to $1.04 billion, or 34 cents a share a year ago. O...

  7. Week Ahead: Earnings Take Center Stage

    Second-quarter earnings take center stage next week with reports from bellwether companies from nearly every important sector of the economy: technology, energy, ind...

  8. Playing Currencies to Your Advantage

    Axel Merk, Merk Investments president and CIO, on how to properly play currencies in today’s headline-driven markets.

  9. EU Body Backs AstraZeneca, Bristol's Diabetes Drug US Rejected

    Advisers to the European drug regulator recommended approval of an experimental diabetes drug that was rejected by U.S. regulators earlier this year amid concerns ab...

  10. Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

    DOW JONES NEWSWIRESA U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in c...

  11. New Jersey Jury Rules For Merck In Another Fosamax Suit

    DOW JONES NEWSWIRESA state court jury in New Jersey has ruled in favor of Merck & Co. (MRK) and rejected a woman's claims that the company's Fosamax drug caused jaw-...

  12. Merck To Pay As Much As $1 Billion To Endocyte For Cancer Drug

    Merck & Co. (MRK) agreed to pay $120 million upfront--and an additional $880 million if certain milestones are met--to Endocyte Inc. (ECYT) for rights to develop and...

  1. Amylin Climbs 6% On Buyout Speculation

    Shares of Amylin Pharmaceuticals climbed 6% in early trading Tuesday after analysts at Leerink Swann said they see Sanofi and Merck emerging as the strongest bidders...

  2. Are CEOs Like Scott Thompson Held to Too High a Standard?

    FBN’s Lou Dobbs on whether there is a decline in leadership in the U.S. or if there is greater accountability.

  3. WSJ BLOG/Health: A.M. Vitals: Pfizer Parts With Lipitor

    Here's what's making health news this morning:Goodbye, Lipitor. Pfizer Bids a Farewell (WSJ): After an $87 million marketing push since November, Pfizer is giving up...

  4. Abbott To Pay $1.6 Billion To Settle Depakote Marketing Probes

    Abbott Laboratories (ABT) agreed to pay $1.6 billion and plead guilty to violating a federal drug law to resolve allegations that the company improperly promoted ant...

  5. Amazon.com, Merck & Included in Stocks Up on High Volume Monday

    These are stocks that are up on high volume today:After trading at a volume of 9.7 million, or 1.6 times its average, Amazon.com (NASDAQ:AMZN) was up on high volume ...

  6. Wall Street Falls Amid Mixed Data

    FOX Business: The Power to ProsperThe markets slipped on Monday as traders mulled mixed U.S. economic data and a bounty of corporate headlines. Today's MarketsAs of ...

  7. US Judge Upholds Validity Of Merck's Vytorin Patent

    A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (MRK) cholesterol-lowering drugs Vytorin and Zetia, which could stave off competing g...

‹ Prev12345…Next ›
Freebase CC-BY
Source: Merck on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL